PMID- 29339100 OWN - NLM STAT- MEDLINE DCOM- 20180817 LR - 20210109 IS - 2352-3964 (Electronic) IS - 2352-3964 (Linking) VI - 28 DP - 2018 Feb TI - Genetic Variation in the Dopamine System Influences Intervention Outcome in Children with Cerebral Palsy. PG - 162-167 LID - S2352-3964(17)30509-1 [pii] LID - 10.1016/j.ebiom.2017.12.028 [doi] AB - BACKGROUND: There is large variation in treatment responses in children with cerebral palsy. Experimental and clinical results suggest that dopamine neurotransmission and brain-derived neurotrophic factor (BDNF) signalling are involved in motor learning and plasticity, which are key factors in modern habilitation success. We examined whether naturally occurring variations in dopamine and BDNF genes influenced the treatment outcomes. METHODS: Thirty-three children (18-60months of age) with spastic unilateral cerebral palsy were enrolled in the study. Each child had participated in a training programme consisting of active training of the involved hand for 2h every day during a 2-month training period. The training outcome was measured using Assisting Hand Assessment before and after the training period. Saliva was collected for genotyping of COMT, DAT, DRD1, DRD2, DRD3, and BDNF. Regression analyses were used to examine associations between genetic variation and training outcome. FINDINGS: There was a statistically significant association between variation in dopamine genes and treatment outcome. Children with a high polygenic dopamine gene score including polymorphisms of five dopamine genes (COMT, DAT, DRD1, DRD2, and DRD3), and reflecting higher endogenous dopaminergic neurotransmission, had the greatest functional outcome gains after intervention. INTERPRETATION: Naturally occurring genetic variation in the dopamine system can influence treatment outcomes in children with cerebral palsy. A polygenic dopamine score might be valid for treatment outcome prediction and for designing individually tailored interventions for children with cerebral palsy. CI - Copyright (c) 2018 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Diaz Heijtz, Rochellys AU - Diaz Heijtz R AD - Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. FAU - Almeida, Rita AU - Almeida R AD - Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. FAU - Eliasson, Ann Christin AU - Eliasson AC AD - Department of Women's and Children's Health, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden. FAU - Forssberg, Hans AU - Forssberg H AD - Department of Women's and Children's Health, Karolinska Institutet, Astrid Lindgren Children's Hospital, Stockholm, Sweden. Electronic address: hans.forssberg@ki.se. LA - eng PT - Clinical Trial PT - Journal Article DEP - 20180109 PL - Netherlands TA - EBioMedicine JT - EBioMedicine JID - 101647039 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 7171WSG8A2 (BDNF protein, human) RN - VTD58H1Z2X (Dopamine) SB - IM MH - Alleles MH - Brain-Derived Neurotrophic Factor/genetics MH - Cerebral Palsy/*genetics MH - Child MH - Child, Preschool MH - Dopamine/*genetics MH - Female MH - Gene Frequency/genetics MH - *Genetic Variation MH - Humans MH - Infant MH - Linear Models MH - Male MH - Multifactorial Inheritance/genetics MH - Treatment Outcome PMC - PMC5835543 OTO - NOTNLM OT - Cerebral palsy OT - Dopamine genes OT - Hand motor assessment OT - Intervention EDAT- 2018/01/18 06:00 MHDA- 2018/08/18 06:00 PMCR- 2018/01/09 CRDT- 2018/01/18 06:00 PHST- 2017/11/21 00:00 [received] PHST- 2017/12/20 00:00 [revised] PHST- 2017/12/22 00:00 [accepted] PHST- 2018/01/18 06:00 [pubmed] PHST- 2018/08/18 06:00 [medline] PHST- 2018/01/18 06:00 [entrez] PHST- 2018/01/09 00:00 [pmc-release] AID - S2352-3964(17)30509-1 [pii] AID - 10.1016/j.ebiom.2017.12.028 [doi] PST - ppublish SO - EBioMedicine. 2018 Feb;28:162-167. doi: 10.1016/j.ebiom.2017.12.028. Epub 2018 Jan 9.